A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder

NCT00880399 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

328

Enrollment

INDUSTRY

Sponsor class

Stopped To allow assessment of isolated events of seizure during program

Conditions

Depressive Disorder, Major

Interventions

DRUG: orvepitant
OTHER: placebo

Sponsor

GlaxoSmithKline